3 results
The objective of this open label phase IIa trial is to evaluate the efficacy and tolerability of a once a week dose of 200 mg R126638, for a maximum of 12 weeks, for the treatment of toenail onychomycosis.
The primary objective of the ADFICE_IT study is to investigate the effects of a CDSS and patient portal for optimizing FRID withdrawal on injurious falls. This study has three secondary objectives. First, we will investigate the effect of the CDSS…
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…